Optimizing management of chronic obstructive pulmonary disease in the upcoming decade

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 47-61

  Russell, Richard ^a   Anzueto, Antonio ^b   Weisman, Idelle ^c  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c PFIZER INC   (United States)

Author keywords

Chronic obstructive pulmonary disease; COPD; Early treatment; Long acting bronchodilator

Indexed keywords

ACLIDINIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; INDACATEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; METHYLXANTHINE; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; ROFLUMILAST; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PROTOCOL; COUGHING; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; FORCED EXPIRATORY VOLUME; HEART ARREST; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; NAUSEA; PNEUMONIA; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH PAIN; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

BRONCHODILATOR AGENTS; EARLY DIAGNOSIS; FORECASTING; HUMANS; LUNG; PATIENT CARE MANAGEMENT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79251468722     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S13758     Document Type: Review

References (81)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2009. Available from: www.goldcopd.com. Accessed 2010 May 12.
2. Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. Int J Tuberc Lung Dis. 2008;12: 703-708.
3. Mannino DM, Buist AS. Global burden of COPD: Risk factors, prevalence, and future trends. Lancet. 2007;370:765-773.
4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.
5. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000;117:S5-S9.
6. Shavelle RM, Paculdo DR, Kush SJ, Mannino DM, Strauss DJ. Life expectancy and years of life lost in chronic obstructive pulmonary disease: Findings from the NHANES III Follow-up Study. Int J Chron Obstruct Pulmon Dis. 2009;4:137-148.
7. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364:709-721.
8. Cooper CB, Dransfield M. Primary care of the patient with chronic obstructive pulmonary disease - Part 4: Understanding the clinical manifestations of a progressive disease. Am J Med. 2008;121 7 Suppl:S33-S45.
9. Wouters EF. Economic analysis of the Confronting COPD survey: An overview of results. Respir Med. 2003;97 Suppl C:S3-S14.
10. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:549-555.
11. Lindberg A, Jonsson AC, Ronmark E, Lundgren R, Larsson LG, Lundbäck B. Prevalence of chronic obstructive pulmonary disease according to BTS, ERS, GOLD and ATS criteria in relation to doctor's diagnosis, symptoms, age, gender, and smoking habits. Respiration. 2005;72:471-479.
12. British Lung Foundation. Invisible lives. Chronic obstructive lung disease (COPD) - finding the missing millions. Available from: http://www.lunguk.org. Accessed 2010 May 12.
13. Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: An analysis of the Framingham offspring cohort. Am J Respir Crit Care Med. 2009;180:3-10.
14. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946.
15. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J. 2007;14 Suppl B:B5-B32.
16. Halpin D. NICE guidance for COPD. Thorax. 2004;59:181-182.
17. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1:1645-1648.
18. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): A prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374:1171-1178.
19. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/ fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: Analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59.
20. Mannino DM, Watt G, Hole D, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J. 2006;27:627-643.
21. Tashkin DP. Frequent exacerbations of chronic obstructive pulmonary disease - a distinct phenotype? New Engl J Med. 2010;363:1183-1184.
22. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New Engl J Med. 2010;363:1128-1138.
23. Bridevaux PO, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz JM, Rochat T. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax. 2008;63:768-774.
24. Ofir D, Laveneziana P, Webb KA, Lam YM, O'Donnell DE. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:622-629.
25. Troosters T, Sciurba F, Battaglia S, et al. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med. 2010; 104:1005-1011.
26. Garcia-Aymerich J, Serra I, Gómez FP, et al. Physical activity and clinical and functional status in COPD. Chest. 2009;136: 62-70.
27. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57: 847-852.
28. Makris D, Moschandreas J, Damianaki A, et al. Exacerbations and lung function decline in COPD: New insights in current and ex-smokers. Respir Med. 2007;101:1305-1312.
29. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebocontrolled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet. 1998;351:773-780.
30. Gompertz S, Bayley DL, Hill SL, Stockley RA. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax. 2001;56:36-41.
31. Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2007; 29:527-534.
32. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. Chest. 2006;129:536-544.
33. Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Baghai-Ravary R, Wedzicha JA. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 179:369-374.
34. Tsai CL, Rowe BH, Camargo CA, Jr. Factors associated with short-term recovery of health status among emergency department patients with acute exacerbations of chronic obstructive pulmonary disease. Qual Life Res. 2009;18:191-199.
35. Groenewegen KH, Dentener MA, Wouters EF. Longitudinal follow-up of systemic inflammation after acute exacerbations of COPD. Respir Med. 2007;101:2409-2415.
36. Glaab T, Banik N, Rutschmann OT, Wencker M. National survey of guideline-compliant COPD management among pneumologists and primary care physicians. COPD. 2006;3:141-148.
37. Rutschmann OT, Janssens JP, Vermeulen B, Sarasin FP. Knowledge of guidelines for the management of COPD: A survey of primary care physicians. Respir Med. 2004;98:932-937.
38. Ta M, George J. Management of COPD in Australia after the publication of national guidelines. Intern Med J. [Epub ahead of print].
39. Derom E, van Weel C, Liistro G, et al. Primary care spirometry. Eur Respir J. 2008;31:197-203.
40. Lusuardi M, De Benedetto F, Paggiaro P, et al. A randomized controlled trial on off ice spirometry in asthma and COPD in standard general practice: Data from spirometry in asthma and COPD: A comparative evaluation Italian study. Chest. 2006;129: 844-852.
41. Arne M, Lisspers K, Ställberg B, Boman G, et al. How often is diagnosis of COPD confirmed with spirometry? Respir Med. 2010;104: 550-556.
42. Jones RC, Dickson-Spillmann M, Mather MJ, Marks D, Shackell BS. Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: The Devon primary care audit. Respir Res. 2008; 9:62.
43. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebocontrolled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002; 122:47-55.
44. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2006;61:91.
45. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month study. Respir Med. 2008;102:1511-1520.
46. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26:214-222.
47. Vincken W. Bronchodilator treatment of stable COPD: Long-acting anticholinergics. Eur Respir Rev. 2005;14:23-31.
48. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 180:741-750.
49. Cazzola M, Dahl R. Inhaled combination therapy with longacting beta 2-agonists and corticosteroids in stable COPD. Chest. 2004;126:220-237.
50. Calverley PM, Anderson JA, Celli B, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-789.
51. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008; 177:19-26.
52. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008;63:592-598.
53. Perng DW, Wu CC, Su KC, Lee YC, Perng RP, Tao CW. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids. Respirology. 2006;11:598-602.
54. Cosio BG, Iglesias A, Rios A, et al. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax. 2009;64:424-429.
55. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2003;3:CD001287.
56. Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR. The effect of oral N-acetylcysteine in chronic bronchitis: A quantitative systematic review. Eur Respir J. 2000;16:253-262.
57. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): A randomised placebo-controlled study. Lancet. 2008;371: 2013-2018.
58. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebo-controlled trial. Lancet. 2005;365: 1552-1560.
59. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009; 64:939-943.
60. Bateman ED. Improving inhaler use in COPD and the role of patient preference. Eur Respir Rev. 2005;14:85-88.
61. Laghi F, Adiguzel N, Tobin MJ. Endocrinological derangements in COPD. Eur Respir J. 2009;34:975-996.
62. Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences - clinical impact, mechanisms, and potential for early intervention. COPD. 2008;5:235-256.
63. Donohue JF, Fogarty C, Lötvall J, et al; INHANCE study investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: Indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182:155-162.
64. Dahl R, Chung KF, Buhl R, et al; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2- agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65:473-479.
65. Soto FJ, Hanania NA. Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med. 2005;11: 129-134.
66. PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials. Lancet. 2009;374:685-694.
67. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbröker D, Bethke TD. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: A randomised controlled trial. Lancet. 2005;366:563-571.
68. LM, Calverley PM, Izquierdo-Alonso JL, Brose M, Martinez FJ, Rabe KF; M2-127 and M2-128 study groups. Roflumilast in moderate-to- severe chronic obstructive pulmonary disease treated with longacting bronchodilators: Two randomised clinical trials. Lancet. 2009; 374:695-703.
69. European Medicines Agency and Committee for Medicinal Products for Human Use. Summary of opinion (initial authorisation). Daxas. Roflumilast. Available from: http://www.ema.europa.eu. Accessed 2010 May 12.
70. Chanez P, et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther. 2010;23:15-21.
71. Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther. 2005;18:75-81.
72. ® Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-1554.
73. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study. Am J Respir Crit Care Med. 2008;178:332-338.
74. Hanania N, Kesten S, Celli B, et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium. Eur Respir J. 2009;34 Suppl 53:S777.
75. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994; 272:1497-1505.
76. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981;1:681-686.
77. Morice AH, Celli B, Kesten S, Lystig T, Tashkin D, Decramer M. COPD in young patients: A pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med. 2010;104:1659-1667.
78. ® trial. Eur Respir J. 2010;36:65-73.
79. Jones P, Harding G, Wiklund I, Berry P, Leidy N. Improving the process and outcome of care in COPD: Development of a standardised assessment tool. Prim Care Respir J. 2009;18:208-215.
80. Martinez FJ, Raczek AE, Seifer FD, et al. Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). COPD. 2008;5:85-95.
81. de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax. 2004;59:120-125.